Figure 3
From: PD-L1 is a critical mediator of regulatory B cells and T cells in invasive breast cancer
CD19+CD24+CD38+ B cell and its subsets are expanded in breast cancer patients.
(A,B) The percentage of CD19+CD24+CD38+ B cells in PBMCs of IBCa patients (10.99 ± 5.70%) was significant higher than in that of FIBma patients (4.48 ± 1.91%) and health individuals (4.49 ± 2.48%) (P < 0.05). (C,D) PD-L1 was detected on CD19+CD24+CD38+ Bregs of breast tumor patients and health individuals. The significant higher CD19+CD24+CD38+PD-L1+ subset (83.74 ± 19.32%) was observed in PBMCs of IBCa patients compared with that in FIBma patients (78.40 ± 13.96%) or health individuals (61.13 ± 20.51%) (P < 0.05). (E,F) The pattern of PD-L1 on CD19+CD24+CD38+ Bregs in PBMCs of IBCa patients was analyzed by cytometry. Wherever PD-L1lo or PD-L1hi expression was significant higher on CD19+CD24+CD38+ Bregs (42.36 ± 23.27% or 14.02 ± 16.99%) than that on Non-Bregs (24.58 ± 16.51% or 3.92 ± 8.18%) in IBCa (P < 0.001 for all).
